Rituximab and cytokine release syndrome

Hrishikesh S. Kulkarni, Pashtoon Murtaza Kasi

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Rituximab is a biologic agent that is usually well tolerated. With its increasing use for a myriad of rheumatologic and immunologic conditions, post-marketing surveillance has revealed more side effects. Systemic inflammatory response syndrome associated with cytokine release syndrome (CRS) is a very rare entity associated with the use of rituximab and carries a very high morbidity and case fatality rate. Cases of CRS reported within the literature are of patients with a very high tumor burden leading to a catastrophic cascade of events. We report the case of a patient having post-transplant lymphoproliferative disorder who died of fatal lactic acidosis and CRS within 24 h of receiving rituximab. Understanding the pathophysiology of such cases and identifying patients at risk may help to possibly avert this life-threatening complication.

Original languageEnglish (US)
Pages (from-to)134-140
Number of pages7
JournalCase Reports in Oncology
Volume5
Issue number1
DOIs
StatePublished - Jan 2012
Externally publishedYes

Fingerprint

Cytokines
Systemic Inflammatory Response Syndrome
Lactic Acidosis
Lymphoproliferative Disorders
Biological Factors
Marketing
Tumor Burden
Morbidity
Transplants
Mortality
Rituximab

Keywords

  • Cytokine release syndrome
  • Fatality
  • Lactic acidosis
  • Mortality
  • Post-transplant lymphoproliferative disorder
  • Rituximab
  • Systemic inflammatory response syndrome

ASJC Scopus subject areas

  • Oncology

Cite this

Rituximab and cytokine release syndrome. / Kulkarni, Hrishikesh S.; Kasi, Pashtoon Murtaza.

In: Case Reports in Oncology, Vol. 5, No. 1, 01.2012, p. 134-140.

Research output: Contribution to journalArticle

Kulkarni, HS & Kasi, PM 2012, 'Rituximab and cytokine release syndrome', Case Reports in Oncology, vol. 5, no. 1, pp. 134-140. https://doi.org/10.1159/000337577
Kulkarni, Hrishikesh S. ; Kasi, Pashtoon Murtaza. / Rituximab and cytokine release syndrome. In: Case Reports in Oncology. 2012 ; Vol. 5, No. 1. pp. 134-140.
@article{8a8b05566ff5457cb0afc2262c7134b0,
title = "Rituximab and cytokine release syndrome",
abstract = "Rituximab is a biologic agent that is usually well tolerated. With its increasing use for a myriad of rheumatologic and immunologic conditions, post-marketing surveillance has revealed more side effects. Systemic inflammatory response syndrome associated with cytokine release syndrome (CRS) is a very rare entity associated with the use of rituximab and carries a very high morbidity and case fatality rate. Cases of CRS reported within the literature are of patients with a very high tumor burden leading to a catastrophic cascade of events. We report the case of a patient having post-transplant lymphoproliferative disorder who died of fatal lactic acidosis and CRS within 24 h of receiving rituximab. Understanding the pathophysiology of such cases and identifying patients at risk may help to possibly avert this life-threatening complication.",
keywords = "Cytokine release syndrome, Fatality, Lactic acidosis, Mortality, Post-transplant lymphoproliferative disorder, Rituximab, Systemic inflammatory response syndrome",
author = "Kulkarni, {Hrishikesh S.} and Kasi, {Pashtoon Murtaza}",
year = "2012",
month = "1",
doi = "10.1159/000337577",
language = "English (US)",
volume = "5",
pages = "134--140",
journal = "Case Reports in Oncology",
issn = "1662-6575",
number = "1",

}

TY - JOUR

T1 - Rituximab and cytokine release syndrome

AU - Kulkarni, Hrishikesh S.

AU - Kasi, Pashtoon Murtaza

PY - 2012/1

Y1 - 2012/1

N2 - Rituximab is a biologic agent that is usually well tolerated. With its increasing use for a myriad of rheumatologic and immunologic conditions, post-marketing surveillance has revealed more side effects. Systemic inflammatory response syndrome associated with cytokine release syndrome (CRS) is a very rare entity associated with the use of rituximab and carries a very high morbidity and case fatality rate. Cases of CRS reported within the literature are of patients with a very high tumor burden leading to a catastrophic cascade of events. We report the case of a patient having post-transplant lymphoproliferative disorder who died of fatal lactic acidosis and CRS within 24 h of receiving rituximab. Understanding the pathophysiology of such cases and identifying patients at risk may help to possibly avert this life-threatening complication.

AB - Rituximab is a biologic agent that is usually well tolerated. With its increasing use for a myriad of rheumatologic and immunologic conditions, post-marketing surveillance has revealed more side effects. Systemic inflammatory response syndrome associated with cytokine release syndrome (CRS) is a very rare entity associated with the use of rituximab and carries a very high morbidity and case fatality rate. Cases of CRS reported within the literature are of patients with a very high tumor burden leading to a catastrophic cascade of events. We report the case of a patient having post-transplant lymphoproliferative disorder who died of fatal lactic acidosis and CRS within 24 h of receiving rituximab. Understanding the pathophysiology of such cases and identifying patients at risk may help to possibly avert this life-threatening complication.

KW - Cytokine release syndrome

KW - Fatality

KW - Lactic acidosis

KW - Mortality

KW - Post-transplant lymphoproliferative disorder

KW - Rituximab

KW - Systemic inflammatory response syndrome

UR - http://www.scopus.com/inward/record.url?scp=84860738843&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84860738843&partnerID=8YFLogxK

U2 - 10.1159/000337577

DO - 10.1159/000337577

M3 - Article

VL - 5

SP - 134

EP - 140

JO - Case Reports in Oncology

JF - Case Reports in Oncology

SN - 1662-6575

IS - 1

ER -